News Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data November 19, 2019 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related DisordersNext →Newly Discovered Drug Is Able To Inhibit Neurotoxic Tau Oligomers In Brains, Paving The Way For A Potential Cure for Alzheimer
